Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 2/20 | 0.49 |
| ▸ | CNR2 | P34972 | 13/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 9/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2039785 | 0.90 | MCL1 (0.52) | MCL1CNR2EGLN1KDM4ECNR1 | |
| SCHEMBL7258425 | 0.88 | MCL1 (0.42) | MCL1CNR2EGLN1CNR1 | |
| SCHEMBL6838299 | 0.82 | MEN1 (0.43) | MCL1CNR2CNR1 | |
| SCHEMBL4154463 | 0.79 | KDM4E (0.38) | KDM4ELMNA | |
| SCHEMBL8908261 | 0.79 | KDM4E (0.48) | KDM4ELMNA | |
| SCHEMBL21648579 | 0.79 | MCL1 (0.46) | MCL1CNR2EGLN1CNR1 | |
| SCHEMBL7033037 | 0.78 | CNR2 (0.42) | CNR2EGLN1CNR1 | |
| SCHEMBL6786479 | 0.77 | MCL1 (0.42) | MCL1CNR2EGLN1BCL2L1 | |
| SCHEMBL2039906 | 0.77 | LMNA (0.47) | MCL1EGLN1KDM4ELMNA | |
| SCHEMBL5434419 | 0.76 | MCL1 (0.41) | MCL1KDM4ELMNACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1020459-B1 | CIS-DISUBSTITUTED AMINOCYCLOALKYL-PYRROLIDINE DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2005-04-06 | — | — | EP | claimed |
| US-8455482-B2 | Substituted pyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-06-04 | — | — | US | disclosed |
| US-7977327-B2 | Substituted pyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20110166131-A1 | SUBSTITUTED PYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-07-07 | — | — | US | disclosed |
| US-20080045520-A1 | Substituted Pyrrolidine Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-02-21 | — | — | US | disclosed |
| US-7186843-B2 | potent antibacterial activity against various bacteria including drug-resistant strains | DAIICHI PHARMACEUTICAL CO. LTD. (JP) | 2007-03-06 | — | — | US | disclosed |
| EP-1757598-A1 | SUBSTITUTED PYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
| EP-1020459-B1 | CIS-DISUBSTITUTED AMINOCYCLOALKYL-PYRROLIDINE DERIVATIVES | DAIICHI SEIYAKU CO (JP) | 2005-04-06 | — | — | EP | disclosed |
| US-20040209940-A1 | Aminomethylpyrrolidine derivatives having aromatic substituents | DAIICHI PHARMACEUTICAL CO., LTD. | 2004-10-21 | — | — | US | disclosed |
| US-6762181-B1 | BROAD ANTIBACTERIAL ACTIVITY INCLUDING DRUG RESISTANT STAPHYLOCOCCUS AUREUS (MRSA), PNEUMOCOCCUS (PRSP) AND ENTEROCOCCUS (VRE); SAFELY USED IN CONJUCTION WITH NONSTEROIDAL ANTIINFLAMMATORY DRUGS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-07-13 | — | — | US | disclosed |
| EP-0947513-A1 | TRICYCLIC AMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-10-06 | — | — | EP | disclosed |
| EP-0529688-B1 | Azaspiro(n,m)alkanes and diazaspiro(n,m)-alkanes | DAIICHI SEIYAKU CO (JP) | 1997-11-12 | — | — | EP | disclosed |
| US-5508428-A | Spiro compound | DAIICHI PHAMACEUTICAL CO., LTD. (JP) | 1996-04-16 | — | — | US | disclosed |
| US-5393758-A | Bactericides, microbiocides | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 1995-02-28 | — | — | US | disclosed |
| US-5393758-A | Bactericides, microbiocides | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 1995-02-28 | — | — | US | disclosed |
| US-5286723-A | Spiro compound | DAIICHI SEIYAKU CO., LTD. | 1994-02-15 | — | — | US | disclosed |
| EP-0357047-B1 | Spiro compounds | DAIICHI SEIYAKU CO (JP) | 1993-11-03 | — | — | EP | disclosed |
| EP-0529688-A2 | Azaspiro n,m alkanes and diazaspiro n,m -alkanes | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1993-03-03 | — | — | EP | disclosed |
| EP-0388298-A2 | Derivatives of pyridone carboxylic acids substituted by an azetidine, their preparation and their use as medicines | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1990-09-19 | — | — | EP | disclosed |
| EP-0357047-A1 | Spiro compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1990-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209940-A1 | Aminomethylpyrrolidine derivatives having aromatic substituents | Q6ZSR9, NAT1, NAT10 | MCL1 1735/4885CNR2 436/4885EGLN1 1174/4885 |
| US-20110166131-A1 | SUBSTITUTED PYRROLIDINE DERIVATIVE | AQP1, GLUL, GATD3 | MCL1 776/4885CNR2 3515/4885EGLN1 879/4885 |
| US-20080045520-A1 | Substituted Pyrrolidine Derivative | QPCT, GMPS, QPCTL | MCL1 1714/4885CNR2 2988/4885EGLN1 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.